Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report
Myeloproliferative neoplasm (MPN) is a clonal proliferation of the haematopoietic stem cells leading to activated tyrosine kinase signaling activity. Myeloproliferative neoplasm is classified into BCR-ABL positive chronic myeloid leukemia (CML) and BCR-ABL negative MPN which harbors JAK2 V617F mutat...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Penerbit Universiti Kebangsaan Malaysia
2023
|
| Online Access: | http://journalarticle.ukm.my/22586/ http://journalarticle.ukm.my/22586/1/m%26h_19.pdf |
| _version_ | 1848815635982712832 |
|---|---|
| author | A, Alia Suzana I, Azlin A, Hafiza Nor Rafeah Tumian, Y, Siti Mariam J, Norunaluwar S, Salwati RZ, Azma |
| author_facet | A, Alia Suzana I, Azlin A, Hafiza Nor Rafeah Tumian, Y, Siti Mariam J, Norunaluwar S, Salwati RZ, Azma |
| author_sort | A, Alia Suzana |
| building | UKM Institutional Repository |
| collection | Online Access |
| description | Myeloproliferative neoplasm (MPN) is a clonal proliferation of the haematopoietic stem cells leading to activated tyrosine kinase signaling activity. Myeloproliferative neoplasm is classified into BCR-ABL positive chronic myeloid leukemia (CML) and BCR-ABL negative MPN which harbors JAK2 V617F mutation in most cases. The genetic combination of BCR-ABL and JAK2 V617F mutation is rare with estimated frequency of 0.4% based on recent study. Herein, we reported a case of a man diagnosed with CML detected by fluorescence in-situ hybdridisation (FISH) showing atypical BCR-ABL fusion pattern in 29% nucleated cells (cut-off levels ≥5% for positive signals) in the presence of JAK2 V617F mutation. However, the BCR-ABL transcript was not detected by the conventional reverse transcriptase-polymerase chain reaction (RT-PCR) method which was specific for major fragments. Interestingly, complete hematological remission was not achieved despite initiation of tyrosine kinase inhibitor (Imatinib). In conclusion, it is imperative to scrutinise CML cases for concomitant JAK2 V617F mutation especially patients with atypical clinical or laboratory findings. Therefore, close monitoring with clinical and ancillary technique especially FISH and molecular methods such as DNA sequencing were crucial to help achieve complete hematological, cytogenetic and deep molecular response alongside targeted therapy. |
| first_indexed | 2025-11-15T00:53:07Z |
| format | Article |
| id | oai:generic.eprints.org:22586 |
| institution | Universiti Kebangasaan Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T00:53:07Z |
| publishDate | 2023 |
| publisher | Penerbit Universiti Kebangsaan Malaysia |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | oai:generic.eprints.org:225862023-11-30T07:17:33Z http://journalarticle.ukm.my/22586/ Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report A, Alia Suzana I, Azlin A, Hafiza Nor Rafeah Tumian, Y, Siti Mariam J, Norunaluwar S, Salwati RZ, Azma Myeloproliferative neoplasm (MPN) is a clonal proliferation of the haematopoietic stem cells leading to activated tyrosine kinase signaling activity. Myeloproliferative neoplasm is classified into BCR-ABL positive chronic myeloid leukemia (CML) and BCR-ABL negative MPN which harbors JAK2 V617F mutation in most cases. The genetic combination of BCR-ABL and JAK2 V617F mutation is rare with estimated frequency of 0.4% based on recent study. Herein, we reported a case of a man diagnosed with CML detected by fluorescence in-situ hybdridisation (FISH) showing atypical BCR-ABL fusion pattern in 29% nucleated cells (cut-off levels ≥5% for positive signals) in the presence of JAK2 V617F mutation. However, the BCR-ABL transcript was not detected by the conventional reverse transcriptase-polymerase chain reaction (RT-PCR) method which was specific for major fragments. Interestingly, complete hematological remission was not achieved despite initiation of tyrosine kinase inhibitor (Imatinib). In conclusion, it is imperative to scrutinise CML cases for concomitant JAK2 V617F mutation especially patients with atypical clinical or laboratory findings. Therefore, close monitoring with clinical and ancillary technique especially FISH and molecular methods such as DNA sequencing were crucial to help achieve complete hematological, cytogenetic and deep molecular response alongside targeted therapy. Penerbit Universiti Kebangsaan Malaysia 2023 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/22586/1/m%26h_19.pdf A, Alia Suzana and I, Azlin and A, Hafiza and Nor Rafeah Tumian, and Y, Siti Mariam and J, Norunaluwar and S, Salwati and RZ, Azma (2023) Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report. Medicine & Health, 18 (1). pp. 233-240. ISSN 2289-5728 https://www.medicineandhealthukm.com/toc/18/1 |
| spellingShingle | A, Alia Suzana I, Azlin A, Hafiza Nor Rafeah Tumian, Y, Siti Mariam J, Norunaluwar S, Salwati RZ, Azma Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report |
| title | Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report |
| title_full | Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report |
| title_fullStr | Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report |
| title_full_unstemmed | Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report |
| title_short | Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report |
| title_sort | concomitant bcr-abl and jak2 v617f in a patient with myeloproliferative neoplasm: a case report |
| url | http://journalarticle.ukm.my/22586/ http://journalarticle.ukm.my/22586/ http://journalarticle.ukm.my/22586/1/m%26h_19.pdf |